Dr. Kalyan Kankanala, Senior Partner, BananaIP Counsels, delivered a class on {inset Slide title}, for National Law School of India University, Bangalore.
Dr. Kalyan Kankanala, Senior Partner, BananaIP Counsels, delivered a class on {inset Slide title}, for National Law School of India University, Bangalore.
Dr. Kalyan Kankanala, Senior Partner, BananaIP Counsels, delivered a class on {inset Slide title}, for National Law School of India University, Bangalore.
The Federal Circuit Review is a monthly newsletter featuring the latest case summaries handed down from the U.S. Court of Appeals for the Federal Circuit.
In this issue:
Doctrine of Equivalents: What Constitutes a Disclosed but not Claimed Equivalent?
When “Each” Means “Every”: Apple Loses a Round in Its Ongoing Battle with Samsung
Capturing Advances in Technology Under the Doctrine of Equivalents
Is a “Height Adjustment Mechanism” a Definite Structure, or a Means-Plus- Function?
PTO Invalidity Ruling Stands Despite Prior Court Ruling of No Invalidity
At a recent Forresters And Knobbe Martens Seminar, Charlotte Teall (Forresters) and Dan Altman (Knobbe Martens) presented "Latest Developments in European Patent Law: How to Apply Them in Both the United States and Europe."
The Federal Circuit Review is a monthly newsletter featuring the latest case summaries handed down from the U.S. Court of Appeals for the Federal Circuit.
In this Issue:
Cancellation of Claims by PTO Binding on District Court
Claims Reciting Method Free of an Agent is Invalid Where Patent Does Not Mention Agent
Defendant Did Not Have Proper Notice of Products Accused of Infringement
Dr. Kalyan Kankanala, Senior Partner, BananaIP Counsels, delivered a class on {inset Slide title}, for National Law School of India University, Bangalore.
Dr. Kalyan Kankanala, Senior Partner, BananaIP Counsels, delivered a class on {inset Slide title}, for National Law School of India University, Bangalore.
The Federal Circuit Review is a monthly newsletter featuring the latest case summaries handed down from the U.S. Court of Appeals for the Federal Circuit.
In this issue:
Doctrine of Equivalents: What Constitutes a Disclosed but not Claimed Equivalent?
When “Each” Means “Every”: Apple Loses a Round in Its Ongoing Battle with Samsung
Capturing Advances in Technology Under the Doctrine of Equivalents
Is a “Height Adjustment Mechanism” a Definite Structure, or a Means-Plus- Function?
PTO Invalidity Ruling Stands Despite Prior Court Ruling of No Invalidity
At a recent Forresters And Knobbe Martens Seminar, Charlotte Teall (Forresters) and Dan Altman (Knobbe Martens) presented "Latest Developments in European Patent Law: How to Apply Them in Both the United States and Europe."
The Federal Circuit Review is a monthly newsletter featuring the latest case summaries handed down from the U.S. Court of Appeals for the Federal Circuit.
In this Issue:
Cancellation of Claims by PTO Binding on District Court
Claims Reciting Method Free of an Agent is Invalid Where Patent Does Not Mention Agent
Defendant Did Not Have Proper Notice of Products Accused of Infringement
On March 14, 2013, Knobbe Martens Partner Carol Pitzel Cruz presented at the 24th C5 Forum on Biotech Patenting 2013. The presentation was titled "The Red Flags Every Patent Attorney Needs to Know to Successfully Navigate the Regulatory Landscape for Biosimilars" and Pitzel Cruz covered the U.S. law.
Her presentation analyzed the key features of the new Food and Drug Administration guidelines for American biosimilar approval under the Biologics Price Competition and Innovation Act.
The Federal Circuit Review is a monthly newsletter featuring the latest case summaries handed down from the U.S. Court of Appeals for the Federal Circuit.
In this issue:
Licensing to Foreign Manufacturers Satisfies Domestic Industry
Appeal Found to Be Moot in Light of “Side Bet”
Mere Design Choice Leads to Obviousness Finding
Design Patent Infringement Complaint Survives Dismissal
In view of the U.S. approval process for biosimilars, companies are gearing up to either produce their own biosimilar products, or to defend against their entry onto the market. While the Biologics Price Competition and Innovation Act (BPCIA) spells out many of the requirements, the pathway for approval is complicated. Our panel of experts discuss the features of the BPCIA and how it operates for both approved biologics as well as biosimilar entrants. They also make some predictions on its impact for life science companies.
The webinar is 60 minutes, complete with Q&A.
The Federal Circuit Review is a monthly newsletter featuring the latest case summaries handed down from the U.S. Court of Appeals for the Federal Circuit.
In this Issue:
• Double Patenting Applies With Distinct Inventive Entities
• Inducement Judgment Remanded in Light of Akamai
• First Sale Doctrine Applies to Sales Made Abroad
The marcus evans 5th Product and Pipeline Enhancement for Generics Conference hosted industry leaders within the Generic Pharmaceutical, Branded Pharmaceutical and API industries operating globally. These leaders shared best practices, strategies and tools on portfolio management and business strategy, as well as legal, intellectual property and patent issues.
Knobbe Martens' attorneys presented on the following topic:
*Analyzing Recent Updates to the Hatch-Waxman Act to Grasp Future Impacts and Challenges
*Studying recent changes that could impact the industry, including 180-day exclusivity and complications regarding patent listings
*Drawing lessons from the close relationship between the patenting of generic products and FDA regulatory approval to pinpoint areas of improvement
*Considering the impact biosimilar products could have on market entry and patent strategies
*Reviewing both real-life rulings and hypotheticals regarding Hatch-Waxman litigation to identify future strategies
Knobbe Martens' Partner Brenden Gingrich presented "Patenting the Unpatentable - Claim Drafting After Prometheus" at the IP Impact 2012 seminar in McLean, Virginia on Wednesday, May 30, 2012. The seminar was designed for corporate counsel, C-Level executives, venture capitalists, entrepreneurs, IP managers and licensing executives.
The Federal Circuit Review is a monthly newsletter featuring the latest case summaries handed down from the U.S. Court of Appeals for the Federal Circuit.
On March 30 and 31, 2017, Knobbe Martens attorneys presented written and oral educational material at an IP Seminar Series “Overseas Intellectual Property Rights Protection for Chinese Enterprises” sponsored by CHOFN, a Chinese IP law firm in Guangzhou and Shenzhen, China.
Paul Conover, Curtis Huffmire and Brent Babcock recently presented at the IN3 Medical Device Summit conference in San Francisco, CA. This presentation covers: recent patent cases from the supreme court, medical device patent statistics and cases, and USPTO Post-Grant Proceedings lessons learned after two years.
Partner Agnes Juang, Ph.D. presented "Navigating the Patent Minefield" at SABPA's 9th Annual Biomedical Forum on Saturday, April 26, at the Crowne Plaza Hotel in Costa Mesa.
The event showcased a number of experts across the pharmaceutical, medical device, and diagnostics industries.
The Federal Circuit Review monthly newsletter is now available. This month’s newsletter covers the latest decisions handed down from the Federal Circuit:
Otsuka Pharmaceutical Co. v. Sandoz Inc.; In Re Youman; In re Montgomery; Leader Technologies, Inc. v. Facebook, Inc.; Apple, Inc. v. Samsung Electronics Co., Ltd.; In Re Baxter International, Inc.; Mintz v. Dietz & Watson, Inc.
On Saturday, May 4, 2013, the Sino-American Biomedical & Pharmaceutical Professionals Association (SABPA) held its 8th Annual Biomedical Forum. The forum focused on career development, entrepreneurship and the latest innovations in pharma/biotech and medical devices industries. The biomedical forum strives to provide an attractive platform for entrepreneurs, scientists, engineers, investors, executives, and policy makers to promote life sciences, biotech, medical device and alliances across the biomedical industry in Southern California and Asian countries. Knobbe Martens Partner Terry Tullis presented on “Commercialization and Patent Infringement.”
The Federal Circuit Review is a monthly newsletter featuring the latest case summaries handed down from the U.S. Court of Appeals for the Federal Circuit.
In this Issue:
Smartphone War Update: Some of Apple’s Patents Survive Invalidity Challenge
• Sale by Foreign Supplier Invalidated Patent
• District Court Abused Discretion in Refusing to Keep Confidential Documents Secret
The Federal Circuit Review is a monthly newsletter featuring the latest case summaries handed down from the U.S. Court of Appeals for the Federal Circuit.
In this issue:
Evidence of Deliberate Decision to Withhold Reference Required for Inequitable Conduct
Licensee Bears Burden of Proving Non-Infringemet in Some Circumstances
No Inequitable Conduct for Failure to Disclose Litigation Involving Parent of Application
Mere Possibility of Allegedly Infringing Activity Insufficient for Declaratory Judgment Jurisdiction
Doctrine of Equivalents Is Available for “Substantially All” Limitation
Court Finds Broadest Reasonable Interpretation of Claim Unreasonable
NEWS FLASH: //Check our latest course offering on Patent-Business-Strategy over at Udemy here: http://www.udemy.com/patent-business-strategy/ with a 50 per cent launch discount //
This a discussion on patent infringement for academic purpose. Please do NOT consider this legal advice.
[Some material has not been updated for recent changes, so use it at your own risk]
Disclaimer: This is not legal advice.
On March 14, 2013, Knobbe Martens Partner Carol Pitzel Cruz presented at the 24th C5 Forum on Biotech Patenting 2013. The presentation was titled "The Red Flags Every Patent Attorney Needs to Know to Successfully Navigate the Regulatory Landscape for Biosimilars" and Pitzel Cruz covered the U.S. law.
Her presentation analyzed the key features of the new Food and Drug Administration guidelines for American biosimilar approval under the Biologics Price Competition and Innovation Act.
The Federal Circuit Review is a monthly newsletter featuring the latest case summaries handed down from the U.S. Court of Appeals for the Federal Circuit.
In this issue:
Licensing to Foreign Manufacturers Satisfies Domestic Industry
Appeal Found to Be Moot in Light of “Side Bet”
Mere Design Choice Leads to Obviousness Finding
Design Patent Infringement Complaint Survives Dismissal
In view of the U.S. approval process for biosimilars, companies are gearing up to either produce their own biosimilar products, or to defend against their entry onto the market. While the Biologics Price Competition and Innovation Act (BPCIA) spells out many of the requirements, the pathway for approval is complicated. Our panel of experts discuss the features of the BPCIA and how it operates for both approved biologics as well as biosimilar entrants. They also make some predictions on its impact for life science companies.
The webinar is 60 minutes, complete with Q&A.
The Federal Circuit Review is a monthly newsletter featuring the latest case summaries handed down from the U.S. Court of Appeals for the Federal Circuit.
In this Issue:
• Double Patenting Applies With Distinct Inventive Entities
• Inducement Judgment Remanded in Light of Akamai
• First Sale Doctrine Applies to Sales Made Abroad
The marcus evans 5th Product and Pipeline Enhancement for Generics Conference hosted industry leaders within the Generic Pharmaceutical, Branded Pharmaceutical and API industries operating globally. These leaders shared best practices, strategies and tools on portfolio management and business strategy, as well as legal, intellectual property and patent issues.
Knobbe Martens' attorneys presented on the following topic:
*Analyzing Recent Updates to the Hatch-Waxman Act to Grasp Future Impacts and Challenges
*Studying recent changes that could impact the industry, including 180-day exclusivity and complications regarding patent listings
*Drawing lessons from the close relationship between the patenting of generic products and FDA regulatory approval to pinpoint areas of improvement
*Considering the impact biosimilar products could have on market entry and patent strategies
*Reviewing both real-life rulings and hypotheticals regarding Hatch-Waxman litigation to identify future strategies
Knobbe Martens' Partner Brenden Gingrich presented "Patenting the Unpatentable - Claim Drafting After Prometheus" at the IP Impact 2012 seminar in McLean, Virginia on Wednesday, May 30, 2012. The seminar was designed for corporate counsel, C-Level executives, venture capitalists, entrepreneurs, IP managers and licensing executives.
The Federal Circuit Review is a monthly newsletter featuring the latest case summaries handed down from the U.S. Court of Appeals for the Federal Circuit.
On March 30 and 31, 2017, Knobbe Martens attorneys presented written and oral educational material at an IP Seminar Series “Overseas Intellectual Property Rights Protection for Chinese Enterprises” sponsored by CHOFN, a Chinese IP law firm in Guangzhou and Shenzhen, China.
Paul Conover, Curtis Huffmire and Brent Babcock recently presented at the IN3 Medical Device Summit conference in San Francisco, CA. This presentation covers: recent patent cases from the supreme court, medical device patent statistics and cases, and USPTO Post-Grant Proceedings lessons learned after two years.
Partner Agnes Juang, Ph.D. presented "Navigating the Patent Minefield" at SABPA's 9th Annual Biomedical Forum on Saturday, April 26, at the Crowne Plaza Hotel in Costa Mesa.
The event showcased a number of experts across the pharmaceutical, medical device, and diagnostics industries.
The Federal Circuit Review monthly newsletter is now available. This month’s newsletter covers the latest decisions handed down from the Federal Circuit:
Otsuka Pharmaceutical Co. v. Sandoz Inc.; In Re Youman; In re Montgomery; Leader Technologies, Inc. v. Facebook, Inc.; Apple, Inc. v. Samsung Electronics Co., Ltd.; In Re Baxter International, Inc.; Mintz v. Dietz & Watson, Inc.
On Saturday, May 4, 2013, the Sino-American Biomedical & Pharmaceutical Professionals Association (SABPA) held its 8th Annual Biomedical Forum. The forum focused on career development, entrepreneurship and the latest innovations in pharma/biotech and medical devices industries. The biomedical forum strives to provide an attractive platform for entrepreneurs, scientists, engineers, investors, executives, and policy makers to promote life sciences, biotech, medical device and alliances across the biomedical industry in Southern California and Asian countries. Knobbe Martens Partner Terry Tullis presented on “Commercialization and Patent Infringement.”
The Federal Circuit Review is a monthly newsletter featuring the latest case summaries handed down from the U.S. Court of Appeals for the Federal Circuit.
In this Issue:
Smartphone War Update: Some of Apple’s Patents Survive Invalidity Challenge
• Sale by Foreign Supplier Invalidated Patent
• District Court Abused Discretion in Refusing to Keep Confidential Documents Secret
The Federal Circuit Review is a monthly newsletter featuring the latest case summaries handed down from the U.S. Court of Appeals for the Federal Circuit.
In this issue:
Evidence of Deliberate Decision to Withhold Reference Required for Inequitable Conduct
Licensee Bears Burden of Proving Non-Infringemet in Some Circumstances
No Inequitable Conduct for Failure to Disclose Litigation Involving Parent of Application
Mere Possibility of Allegedly Infringing Activity Insufficient for Declaratory Judgment Jurisdiction
Doctrine of Equivalents Is Available for “Substantially All” Limitation
Court Finds Broadest Reasonable Interpretation of Claim Unreasonable
NEWS FLASH: //Check our latest course offering on Patent-Business-Strategy over at Udemy here: http://www.udemy.com/patent-business-strategy/ with a 50 per cent launch discount //
This a discussion on patent infringement for academic purpose. Please do NOT consider this legal advice.
[Some material has not been updated for recent changes, so use it at your own risk]
Disclaimer: This is not legal advice.
Patent infringement Analysis - IPRL Class on Paper II : Law of Patents: by D...BananaIP Counsels
Dr. Kalyan explained the concept of patent infringement, assessing literal infringement and infringement by doctrine of equivalence with examples. The infringement test used in the Indian courts was also discussed. Please find the presentation below for your reference.
Intellectual property (IP) is a valuable asset for any company, and patent infringement can have a significant impact on the business. In India, patent infringement lawsuits are on the rise, and some of them have resulted in substantial settlements or verdicts. In this video, we will look at the 10 most famous Indian patent lawsuits.
If you need a patent licensing expert who not only understands the technology, industry, and your specific needs, but also stay with you on each step during monetization process and make sure you get the results crucial for your win, then you are at the right place. Our experts, at Boolean IP, have a total experience of conducting 100+ successful patent infringement identification searches. Clubbing the experience and expertise of our techno-legal experts, and AI-powered tools, Boolean IP provides high quality IP solutions that help you win. Get in touch with your queries.
#patentinfringements #patentlicenses #patentroyalty #infringements #patentrolls #infringers #patentmonetization #patentsearch #novelty #patentability #Freedomtooperate #FTO #booleanipconsulting
Dr. Kalyan Kankanala, Senior Partner, BananaIP Counsels, delivered a class on {inset Slide title}, for National Law School of India University, Bangalore.
Intellectual Property Rights Protection in Food Industry: An Indian Perspective Workshop was conducted on March 21, 2016 at Better Process Control School (USFDA). The venue for the workshop was Bhaskaracharya College of Applied Sciences (BCAS), University of Delhi.
Currently, a lot research and development is taking place in food based industries in India. Indian food manufacturers produce hundreds of different varieties of vacuum packed ready-to-eat dinner entrees that are imported into the United States. Before 2011, no in-country Better Process Control School (BPCS) was available for the Indian food based manufacturers. Currently, Better Process Control School (BPCS) is being managed by Bhaskaracharya College of Applied Sciences (BCAS), University of Delhi.
Nevertheless, the importance of intellectual property right protection for food based industry is very important. The agenda of the intellectual property based presentation was to ensure that Indian Market players are able to compete well with MNCs in Global Marketplace.
Сергей Уляхин "Аспекты коммерциализации интеллектуальной собственности" (S.Ul...EconMsu
Лекция Сергея Уляхина про особенности коммерциализации интеллектуальной собственности.
Лекция была проведена в рамках межфакультетского курса МГУ "Экономика инноваций: как запустить технологический проект?". Подробнее о курсе - https://vk.com/mfk_ei
Your IP Strategy & Patent Litigation Support Partner | Patent Research & Technology Intelligence Services| Patent Analysis Services
We help our medical device clients with technology intelligence services which is helpful to develop IP strategies. In addition, we provide research support to finalise the prototype of the Medical diagnostic kits. Over the years we have executed more than 100+ intellectual property research and analysis projects in the medical diagnostic domain.
Generally after analysing the patent results the decision makers are able to understand the market dynamics.
Indian Intellectual Property Cases Report, 2021.pdfBananaIP Counsels
BananaIP is happy to launch the IP Cases Report for the year 2021. This report covers cases related to intellectual property decided by Courts in India, in the form of case notes. These case notes cover important decisions on critical questions of law and fact with respect to various species of intellectual property.
Digital health is all around us and the health tech sector has been taking off like a rocket. Spurred by advancements in AI, ML, and mobile device tech combined with challenges brought on by everything from the needs of daily health monitoring to the challenges that came along with the pandemic. These worlds are colliding, innovation in the sector is exploding, and disruptive change to healthcare will only accelerate.
Amidst all of this massive growth, startups need to maximize their use of funding and protect their IP from being copied. Patents are the strongest form of protection against this and one of the best possible returns on investment.
At the most basic level, if your innovations drive your product and your business, it’s essential to develop a patent strategy that protects these innovations, increases your valuation, and extends your company’s longevity.
So, growth is incredible. Patents provide great protection and can yield incredible ROI. So what’s the problem?
Patent law and court rulings have been working in direct opposition to this growth, but there are some key strategies you can leverage to make the most of your funds while securing vital intellectual property.
Capsule Endoscopy Patent Landscape Flyer 2014
Olympus and Given Imaging are leading intellectual property in the capsule endoscopy industry, but for how long?
KEY FEATURES OF THE REPORT
The report provides essential patent data for capsule endoscopy. It identifies more than 30 major holders of capsule endoscopy related intellectual property. It provides in-depth IP analysis and industrial key players including:
-Time evolution of patent publications and countries of patent filings.
-Current legal status of patents.
-Ranking of main patent applicants.
-Joint developments and IP collaboration network of main patent applicants.
-Key patents.
-Granted patents near expiration.
-Relative strength of main companies IP portfolio.
-Overview of patent litigations.
-Matrix applicants/technology issues for more than 15+ companies.
The “capsule endoscopy IP” profiles of 15+ major companies is presented, with key patents, technological issues, litigations, licenses, partnerships, and IP strength and strategy.
The report also provides an extensive Excel database with all patents analyzed in the report.
OBJECTIVE OF THE REPORT
•Understand the IP landscape for capsule endoscopy.
•Identify key patents.
•Understand trends in capsule endoscopy IP.
•Identify the major players in capsule
endoscopy IP and the relative strength of
their patent portfolio.
•Identify new players in capsule endoscopy IP.
•Identify IP collaboration networks between key players (industrial and academics).
•Identify main patent litigations.
The Proposed Trade Marks (1st Amendment) Rules, 2024BananaIP Counsels
Deadline for Public Comments on New Trade Mark Draft Rules 2024 Ends Today, February 9th, 2024
The Ministry of Commerce and Industry, through its Department for Promotion of Industry and Internal Trade, issued a notification on January 2nd, 2024, regarding the draft rules to amend the Trade Marks Rules, 2017. Published in the Gazette of India, this notification invites public feedback and suggestions on the proposed changes.
Read more: https://www.bananaip.com/ip-news-center/trade-marks-1st-amendment-rules-2024-comments-deadline/
Generative AI (GenAI), Business and Intellectual PropertyBananaIP Counsels
The extent of protectability and enforceability of inventions and creations of Generative (Gen) AI is today the subject of discussions and debates among professional and academic circles. While Courts in some countries have decided on protectability of Gen AI, and the role of human intervention required for such protection, several questions remain unanswered. The enforceability of Gen AI also raises several questions at various levels. Read more - https://www.bananaip.com/ip-news-center/generative-ai-genai-business-and-intellectual-property/
If you have any questions, speak with an IP expert/attorney – contact@bananaip.com or 91-80-26860414/24/34.
Guidelines on Film Accessibility in India: Comments and SuggestionsBananaIP Counsels
On 8th January 2024, the Ministry of Information and Broadcasting (MoIB) published a draft of the Guidelines of Accessibility Standards in the Public Exhibition of Feature Films in Cinema Theatres for Persons with hearing and visual impairments (hereinafter “Guidelines”). These Guidelines are expected to be applicable for those feature films that are certified by the Central Board of Film Certification (CBFC) for public exhibition in cinema halls/movie theatres for commercial purposes. The Guidelines were made available for public scrutiny on 8th January 2024, seeking comments and suggestions by 31st January 2024. In response, the accessibility law attorney team at BananaIP Counsels (“BananaIP”) is hereby submitting comments and suggestions for the MoIB’s consideration. The comments and suggestions submitted herein are based on our ground-level experience of facilitating and implementing accessibility standards and are being submitted with the bonafide intent of enabling the MoIB to improve the guidelines based on implementation level feedback.
The views expressed in the submissions are those of the authors and do not reflect the views of BananaIP, other attorneys in the firm, or its clients.
Indian Design Statistics for 2023 By BananaIP CounselsBananaIP Counsels
The Indian Design Statistics Report for the year 2023 has been prepared by BananaIP Counsels as a part of its knowledge dissemination initiatives. The report is based on the information and data available on the Indian Intellectual Property (IP) Office website and databases and is accurate to the extent of data publication, availability, and searchability.
For the latest IP news updates visit: www.bananaip.com
Email: contact@bananaip.com
Indian Patent Statistics for 2023 by BananaIP CounselsBananaIP Counsels
BananaIP is pleased to release the 2023 Patent Statistics Report. This document offers a comprehensive overview of patent activities in India, including publications, examinations, grants, and refusals. It compares data from 2019 to 2023 and includes city-wise patent statistics and performance metrics of various patent offices.
The Draft Indian Patent Rules 2024 has been released for public review. This document primarily addresses the adjudication process for penalties in patent-related matters. It introduces specific roles such as 'Adjudicating Officer' and 'Appellate Authority', clarifying their functions in the patent adjudication process. The draft also details procedures for filing and appealing complaints in cases of patent contraventions.
These updates are part of an ongoing effort to enhance the clarity and efficiency of the patent process in India. Stakeholders are encouraged to submit their feedback by February 1st, 2024.
If you have any questions, speak with a Patent expert/attorney – contact@bananaip.com or 91-80-26860414/24/34.
Patent Examination and Pre-Grant Opposition are independent processes, says t...BananaIP Counsels
In an appeal filed by Novartis from the decision of a Single Judge, the Division Bench of the Delhi High Court considered if a pre-grant opponent would have the right to participate and get a hearing with respect to amendments made by the patent applicant based on directions of the Controller of Patents. The pre-grant oppositions in the case were filed by NATCO and several others, and the Single Judge held that pre-grant opponents have to be heard with respect to all amendments as the patent examination and pre-grant opposition processes merge once a representation is accepted by the Controller. Disagreeing with the Single Judge, the Division Bench held that patent examination and pre-grant opposition are independent and separate processes.
If you have any questions, speak with a Patent expert/attorney – contact@bananaip.com or 91-80-26860414/24/34.
In the case of Huhtamaki Oyj And Anr Vs Controller Of Patents at the Delhi High Court, a significant development has transpired. The focus was on a Polymer Technology patent application titled “An Essentially Biobased Thermoformable Composition And Containers Formed Thereof”.
The application had encountered objections concerning its inventive step and non-patentability. The Court highlighted the need for a thorough examination in the decision-making process.
After detailed reconsideration, it's confirmed that the patent was granted on 26th July 2023. This case emphasizes the critical role of comprehensive examination in the patent granting process and the resilience necessary from applicants.
#BananaIP #PatentLaw #DelhiHighCourt #InnovationProtection #PolymerTechnology #PatentGranted #IntellectualProperty
IP For Business - Presentation by Dr. Kalyan at IIM - Bangalore (2023 Class o...BananaIP Counsels
On August 3rd, 2023, Dr. Kalyan from BananaIP shared insights on 'IP for Business' with the 2023 EPGP class at IIMB. As we continue our journey, we appreciate your interest and engagement with our ongoing efforts.
www.bananaip.com
#BananaIP #DrKalyan #IPforBusiness #IIMBangalore #EPGP2023 #IntellectualProperty #IPInsights #BusinessStrategy #EducationInitiative #KnowledgeSharing
INDIAN INTELLECTUAL PROPERTY STATISTICS REPORT, 2021BananaIP Counsels
BananaIP is happy to launch the IP statistics report for the year 2021. This report covers Patent, Trademark, Design, Copyright and Geographical Indication (GI) statistics based on information available on the website of the Indian IP Office. Wherever relevant, a comparative review with previous years has been presented in the report.
Findings and Conclusions
At a general level, intellectual property activity before the IP Office increased notably in 2021 compared to the previous year. While Patent, Copyright, Trademark, and GI filings saw an increase in numbers, the number of Design filings dropped during the year.
The conclusion of the report reads as follows:
"To conclude, we observed an overall increase in the IP Statistics in 2021. In the year 2021 number of patents published increased by 2%, the number of trademarks filed increased by 13.78%, the number of copyrights filed increased by 29.71% and the number of geographical indications filed increased by 49.01%. We also observed that the number of patents granted increased by 15.66%, trademarks registered increased by 33.96%, and geographical indications registered increased by 560% in 2021. However, the number of designs registered decreased by 17.54%."
Statistics as Indicators
Intellectual Property statistics have since long been used as indicators of intellectual activity, and the findings of this report signify an increase in innovative and creative activity in India despite the pandemic. The numbers also indicate the importance being given to IP protection in the Indian market by both Indian and foreign organisations.
Talking about the report, Dr. Kalyan C. Kankanala stated, "IP filings in India have been steadily increasing since 2014, and the increase in 2021 is not surprising. What is interesting is the fact that patent, trademark, and other IP filings increased despite the negative consequences of COVID-19.
The increase in numbers is in sync with increased enforcement, licensing, and litigation.
Over the last decade, we have seen a significant transformation in the IP ecosystem in India, and I can today state with confidence that we are no longer a nation that views IP with circumspection."
Attribution
The report was the result of contributions from consulting/strategy, patent, copyright, and trademark departments of BananaIP Counsels.
In this presentation, we bring to you a recap of the IP statistics from 2021 and a comparison of these numbers with the statistics from 2019 and 2020. The data is calculated for the respective calendar years (January to December). It will be different from the data published by the respective offices as they calculate the data for the respective financial year.
Dr. Kalyan Kankanala, Senior Partner, BananaIP Counsels, delivered a class on {inset Slide title}, for National Law School of India University, Bangalore.
A presentation on Patent Registration Process by Ms. Anjali Santhosh BananaIP Counsels
Ms. Anjali Santhosh, Senior Associate at BananaIP Counsels delivered a webinar session on Patent Registration Process at Kristu Jayanti College for Law and Economics students on the 14th of August, 2020. The webinar event was attended by over a 200 participants and was primarily aimed at helping students and faculties to understand the process and importance of Patents.
WINDING UP of COMPANY, Modes of DissolutionKHURRAMWALI
Winding up, also known as liquidation, refers to the legal and financial process of dissolving a company. It involves ceasing operations, selling assets, settling debts, and ultimately removing the company from the official business registry.
Here's a breakdown of the key aspects of winding up:
Reasons for Winding Up:
Insolvency: This is the most common reason, where the company cannot pay its debts. Creditors may initiate a compulsory winding up to recover their dues.
Voluntary Closure: The owners may decide to close the company due to reasons like reaching business goals, facing losses, or merging with another company.
Deadlock: If shareholders or directors cannot agree on how to run the company, a court may order a winding up.
Types of Winding Up:
Voluntary Winding Up: This is initiated by the company's shareholders through a resolution passed by a majority vote. There are two main types:
Members' Voluntary Winding Up: The company is solvent (has enough assets to pay off its debts) and shareholders will receive any remaining assets after debts are settled.
Creditors' Voluntary Winding Up: The company is insolvent and creditors will be prioritized in receiving payment from the sale of assets.
Compulsory Winding Up: This is initiated by a court order, typically at the request of creditors, government agencies, or even by the company itself if it's insolvent.
Process of Winding Up:
Appointment of Liquidator: A qualified professional is appointed to oversee the winding-up process. They are responsible for selling assets, paying off debts, and distributing any remaining funds.
Cease Trading: The company stops its regular business operations.
Notification of Creditors: Creditors are informed about the winding up and invited to submit their claims.
Sale of Assets: The company's assets are sold to generate cash to pay off creditors.
Payment of Debts: Creditors are paid according to a set order of priority, with secured creditors receiving payment before unsecured creditors.
Distribution to Shareholders: If there are any remaining funds after all debts are settled, they are distributed to shareholders according to their ownership stake.
Dissolution: Once all claims are settled and distributions made, the company is officially dissolved and removed from the business register.
Impact of Winding Up:
Employees: Employees will likely lose their jobs during the winding-up process.
Creditors: Creditors may not recover their debts in full, especially if the company is insolvent.
Shareholders: Shareholders may not receive any payout if the company's debts exceed its assets.
Winding up is a complex legal and financial process that can have significant consequences for all parties involved. It's important to seek professional legal and financial advice when considering winding up a company.
ALL EYES ON RAFAH BUT WHY Explain more.pdf46adnanshahzad
All eyes on Rafah: But why?. The Rafah border crossing, a crucial point between Egypt and the Gaza Strip, often finds itself at the center of global attention. As we explore the significance of Rafah, we’ll uncover why all eyes are on Rafah and the complexities surrounding this pivotal region.
INTRODUCTION
What makes Rafah so significant that it captures global attention? The phrase ‘All eyes are on Rafah’ resonates not just with those in the region but with people worldwide who recognize its strategic, humanitarian, and political importance. In this guide, we will delve into the factors that make Rafah a focal point for international interest, examining its historical context, humanitarian challenges, and political dimensions.
NATURE, ORIGIN AND DEVELOPMENT OF INTERNATIONAL LAW.pptxanvithaav
These slides helps the student of international law to understand what is the nature of international law? and how international law was originated and developed?.
The slides was well structured along with the highlighted points for better understanding .
Military Commissions details LtCol Thomas Jasper as Detailed Defense CounselThomas (Tom) Jasper
Military Commissions Trial Judiciary, Guantanamo Bay, Cuba. Notice of the Chief Defense Counsel's detailing of LtCol Thomas F. Jasper, Jr. USMC, as Detailed Defense Counsel for Abd Al Hadi Al-Iraqi on 6 August 2014 in the case of United States v. Hadi al Iraqi (10026)
1. Copyright, BananaIP (BIP) Counsels, 2021
Patent Defenses
Dr. Kalyan C. Kankanala
BananaIP Counsels
contact@bananaip.com
2. Patent Invalidity
• Patentability
• Prior Art - Gillette Defense
• Wrongful Obtainment
• False Representation/Information
• Secret Use
• Section 8 - IUFA (Information and Undertaking
with respect to Foreign Applications)
Copyright, BananaIP (BIP) Counsels, 2021
3. Example
X acquires a patent on a method of styling hair based on the
texture and the length of one’s hair. Y, a hair stylist, uses the method
to service clients and publishes a video of the same on YouTube. X
sues Y for patent infringement.
Y claims patent invalidity based on prior public knowledge and use.
She states that hair stylists have been using the technique for a long
time.
Y claims that she is not infringing the patent because what she is
doing was being practiced for several centuries. She produces
ancient documents regarding the same.
Does Y have valid defenses? Is she liable for patent infringement?
Copyright, BananaIP (BIP) Counsels, 2021
4. Example
X’s patent application gets rejected in Europe, but X does not
inform the Indian Patent Office.
X’s patent application in the United States gets granted, and X does
not inform the Indian Patent Office.
X’s patent application gets published in Singapore, but X does not
get an update from the Singapore attorney. Therefore, X does not
disclose the same to the Indian Patent Office.
Y challenges validity of X’s patent on all the above grounds. Is the
patent invalid based on any of the grounds?
Copyright, BananaIP (BIP) Counsels, 2021
5. Research Exemption
• Machine, Apparatus or any other Article - Make
and Use
• Process - Use
• Research or Experiment
• Instruction to Pupils
Copyright, BananaIP (BIP) Counsels, 2021
6. Bolar Exemptions
• Product - Make, Construct, Use, Sell and Import
❖ Submission and Development of Information.
❖ Required under any Regulatory Law
Copyright, BananaIP (BIP) Counsels, 2021
7. Example
XBio wishes to launch a vaccine as soon as the patent on the
vaccine expires. Towards the said end, it initiates clinical studies and
trials while the patent is valid. Some of its studies are conducted in
China. To facilitate the same, XBio sends the vaccine to a Chinese
company.
Aggrieved, YPharma, the patent holder of the vaccine sues XBio for
patent infringement.
Copyright, BananaIP (BIP) Counsels, 2021
8. Government Use
• Machine, Apparatus and Other Article - Make and Import
• Process – Use
❑ Government’s Own Use
❑ On behalf of the Government for its Own Use
Copyright, BananaIP (BIP) Counsels, 2021
9. Example
DayLight owns a patent for implementing day lighting systems in old
buildings. The Railway Department publishes a tender calling for
proposals to implement day lighting solutions in Bangalore railway
stations. DayLight bids for the same, but does not get selected.
The selected company, SunLight, uses DayLight's patent for
implementing day lighting systems. Aggrieved, DayLight sues
SunLight and the Railway Department.
Are SunLight and the Railway Department liable?
Copyright, BananaIP (BIP) Counsels, 2021
10. Parallel Imports
• Importation
➢ Patented Products
➢ From a Person Authorized - Produce and Sell or Distribute
➢ Authorized under the Law
Copyright, BananaIP (BIP) Counsels, 2021
11. Example
Public Labs, a company head quartered at Mysore, places an order with a
lab in Israel to make Covar to combat the ongoing COVID-19 crisis in India.
Covar is patented by India Bio, a vaccine company, and ICMR. Covar is not
patented in Israel.
The Israeli company delivers one million doses of the vaccine to Public Labs,
which distributes the same to private hospitals for free. Aggrieved, India Bio
and ICMR sue Public Labs for patent infringement.
Is Public Labs liable?
Copyright, BananaIP (BIP) Counsels, 2021